Spots Global Cancer Trial Database for philadelphia chromosome
Every month we try and update this database with for philadelphia chromosome cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia | NCT00852566 | Chronic Myeloid... | Imatinib Dasatinib | 18 Years - | Norwegian University of Science and Technology | |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | NCT00171249 | Philadelphia Po... Acute Lymphobla... Acute Myeloid L... | STI571 400 mg STI571 600 mg | 18 Years - | Novartis | |
| Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) | NCT01724879 | Philadelphia Po... | Dasatinib | 18 Years - 55 Years | Goethe University | |
| An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia | NCT00171249 | Philadelphia Po... Acute Lymphobla... Acute Myeloid L... | STI571 400 mg STI571 600 mg | 18 Years - | Novartis | |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | NCT01511289 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Bone Marrow Dis... Hematologic Dis... | Imatinib Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | NCT00261846 | Chronic Myeloid... | Bosutinib | 18 Years - | Pfizer | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | NCT01471067 | Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation... | Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03509896 | Chronic Myeloid... Philadelphia Ch... Chronic Myeloid... | Non-Interventio... | 18 Years - | Bristol-Myers Squibb | |
| Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation | NCT01243489 | Chronic Myeloge... | compliance supp... | 18 Years - | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias | NCT00261846 | Chronic Myeloid... | Bosutinib | 18 Years - | Pfizer | |
| Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in Children | NCT00287105 | Acute Lymphobla... Philadelphia Ch... | Standard chemot... | 1 Year - 18 Years | Rennes University Hospital | |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | NCT01511289 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Bone Marrow Dis... Hematologic Dis... | Imatinib Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP | NCT04971226 | Chronic Myeloid... | Imatinib Nilotinib Bosutinib Dasatinib Asciminib | 18 Years - | Novartis | |
| TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | NCT01883219 | Philadelphia Ch... Stem Cell Trans... Minimal Residua... | TKIs | 14 Years - 65 Years | Nanfang Hospital, Southern Medical University | |
| Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) | NCT03509896 | Chronic Myeloid... Philadelphia Ch... Chronic Myeloid... | Non-Interventio... | 18 Years - | Bristol-Myers Squibb | |
| Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia | NCT00511303 | Chronic Myeloid... | STI571 | 18 Years - | University of Bologna | |
| An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha | NCT00171223 | Leukemia, Myelo... | STI571 | 18 Years - | Novartis | |
| Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI | NCT01602952 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Hematologic Dis... | Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis | NCT00171158 | Philadelphia Ch... | imatinib mesyla... | 18 Years - | Novartis | |
| A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT02130557 | Leukemia, Myelo... | Bosutinib Imatinib | 18 Years - | Pfizer | |
| Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | NCT02523976 | Acute,Leukemia,... | Dasatinib prednisone cyclophosphamid... daunorubicin vincristine cytarabine mercaptopurine methotrexate dexamethasone mitoxantrone etoposide allogeneic hema... autologous hema... | 18 Years - 55 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| An Extension Study of the Safety and Anti-leukemic Effects of Imatinib Mesylate in Participants With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Blast Crisis | NCT00171158 | Philadelphia Ch... | imatinib mesyla... | 18 Years - | Novartis | |
| Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients | NCT01511289 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Philadelphia Ch... Bone Marrow Dis... Hematologic Dis... | Imatinib Radotinib | 18 Years - | Il-Yang Pharm. Co., Ltd. | |
| Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies | NCT01471067 | Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation... | Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Protein-Tyrosine Kinase Inhibitor (STI571) for Treatment of Patients With Ph+ Chronic Myeloid Leukemia | NCT00511303 | Chronic Myeloid... | STI571 | 18 Years - | University of Bologna | |
| Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients | NCT01254188 | Chronic Myeloid... | Nilotinib | 18 Years - | Novartis | |
| Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation | NCT01243489 | Chronic Myeloge... | compliance supp... | 18 Years - | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| Retrospective Observational Research Study to Describe the Real World Use of Bosutinib in a Single Centre in Scotland | NCT05363488 | Myeloid Leukemi... | Bosutinib | 18 Years - | Pfizer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
